Alexander Gintsburg, scientific director of the Gamaleya National Center for Epidemiology and Microbiology Research, reported on Tuesday (May 5, 2026) that only a slight rise in temperature was recorded after administering the cancer vaccine.

According to him, the first patient who received the cancer vaccine did not suffer from any serious adverse reactions after receiving it, with only one slight rise in body temperature recorded.

He said: "There were no side effects. There was a slight rise in temperature once, as usually happens when giving any vaccine, nothing more."

Gintsburg explained that the patient who received the vaccine suffers from stage three cancer.

It is worth noting that on April 1 of last month, the first patient in Russia received the personalized cancer vaccine, designated for treating melanoma skin cancer, "Neoncovac," produced by the National Center for Radiation Medical Research affiliated with the Russian Ministry of Health, and developed in cooperation with the Gamaleya National Center and the Blokhin National Medical Research Center of Oncology.

This drug is used to treat adult patients with inoperable or metastatic melanoma skin cancer.